Chimerix (NASDAQ:CMRX) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.09, Fidelity Earnings reports. Chimerix had a negative return on equity of 34.94% and a negative net margin of 1,582.64%. The business had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $0.97 million.

Chimerix stock traded down $0.17 during midday trading on Friday, reaching $3.32. 84,193 shares of the company were exchanged, compared to its average volume of 215,341. The stock has a market cap of $172.41 million, a PE ratio of -2.20 and a beta of 1.20. Chimerix has a 1 year low of $3.11 and a 1 year high of $5.94.

A number of research analysts have recently weighed in on the company. Cowen restated a “hold” rating and issued a $6.00 price target on shares of Chimerix in a research report on Thursday, October 18th. Zacks Investment Research cut Chimerix from a “buy” rating to a “hold” rating in a research report on Tuesday, October 9th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Chimerix in a research report on Friday, September 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $6.75.

A number of institutional investors have recently bought and sold shares of CMRX. Wells Fargo & Company MN increased its position in Chimerix by 46.1% during the 1st quarter. Wells Fargo & Company MN now owns 33,569 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 10,598 shares in the last quarter. Dimensional Fund Advisors LP increased its position in Chimerix by 12.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,317,142 shares of the biopharmaceutical company’s stock worth $12,049,000 after purchasing an additional 259,424 shares in the last quarter. Millennium Management LLC increased its position in Chimerix by 229.2% during the 1st quarter. Millennium Management LLC now owns 253,533 shares of the biopharmaceutical company’s stock worth $1,318,000 after purchasing an additional 176,509 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Chimerix by 153.6% during the 2nd quarter. Assenagon Asset Management S.A. now owns 711,498 shares of the biopharmaceutical company’s stock worth $3,387,000 after purchasing an additional 430,891 shares in the last quarter. Finally, Acadian Asset Management LLC increased its position in Chimerix by 63.3% during the 2nd quarter. Acadian Asset Management LLC now owns 155,067 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 60,087 shares in the last quarter. Hedge funds and other institutional investors own 71.85% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first published by Daily Political and is the property of of Daily Political. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.dailypolitical.com/2018/11/10/chimerix-cmrx-posts-earnings-results-beats-estimates-by-0-09-eps.html.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

See Also: Bear Market

Earnings History for Chimerix (NASDAQ:CMRX)

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.